Company intelligence / Profile preview

Abgenix

Fremont, California, United Statesabgenix.com ↗

Ownership: Private
Development stage: Commercial

Overview

Abgenix developed the XenoMouse platform for generating fully human monoclonal antibodies. Its lead product panitumumab (Vectibix) showed efficacy in slowing progression of advanced colorectal cancer and was later approved by the FDA. Other programs included anti-inflammatory and immunomodulatory antibody candidates. The company was acquired by Amgen in 2006 for $2.2 billion to gain full control over its antibody pipeline and technology platforms

Therapeutic areas: OncologyImmunologyInfectious Diseases
Modalities: monoclonal antibodies (mAbs)fully human antibodies
Industry: Biotech

Drug pipeline

2 assets

panitumumab

Commercial

Indications: Colorectal cancer, Head and neck cancer

1 more asset in the full pipeline.

Request access →

Partnerships

AmgenBristol Myers SquibbMerck

Beyond the preview

Go deeper on Abgenix.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Abgenix.

Explore the full profile